Oversight and Monitoring of Blood Safety in the United States
暂无分享,去创建一个
R. Khabbaz | S. Kleinman | M. Busch | M. Chamberland | J. Epstein | G. Nemo | M. Busch
[1] R. Koup,et al. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. , 1998, The Journal of infectious diseases.
[2] P. Brown,et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy , 1998, Transfusion.
[3] S. DeArmond,et al. Surveillance for Creutzfeldt‐Jakob disease among persons with hemophilia , 1998, Transfusion.
[4] G A Satten,et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. , 1998, JAMA.
[5] L. Corash,et al. Inactivation of Viruses, Bacteria, Protozoa, and Leukocytes in Platelet Concentrates , 1998, Vox sanguinis.
[6] J. Menitove. Hemovigilance in the United States of America , 1998, Vox sanguinis.
[7] L. Williamson,et al. Haemovigilance: Concept, Europe and UK Initiatives , 1998, Vox sanguinis.
[8] J. Debeir,et al. The French Hæmovigilance System , 1998 .
[9] J. Bethel,et al. Estimates of Infectious Disease Risk Factors in U.S. Blood Donors , 1998 .
[10] R. Dodd,et al. Creutzfeldt‐Jakob disease and transfusion safety: tilting at icebergs? , 1998, Transfusion.
[11] E. Fiebig,et al. Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole‐blood samples , 1998, Transfusion.
[12] H. Webster,et al. Lymphocyte subset analysis on frozen whole blood. , 1997, Cytometry.
[13] E. Read,et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. , 1997, The Journal of infectious diseases.
[14] S. Kleinman,et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. , 1997, Transfusion medicine reviews.
[15] D. Stram,et al. Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. The Transfusion Safety Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[16] D. Fuchs,et al. Blood donations and viruses , 1997, The Lancet.
[17] A. Williams,et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. , 1997, JAMA.
[18] M P Busch,et al. Divergence of HIV‐1 quasispecies in an epidemiologic cluster , 1997, AIDS.
[19] R. Wesley,et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. , 1997, The New England journal of medicine.
[20] H. Margolis,et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. , 1997, The New England journal of medicine.
[21] T. Surowy,et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. , 1997, The Journal of infectious diseases.
[22] M. Alter,et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. , 1996, JAMA.
[23] R. Holman,et al. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. , 1996, Emerging infectious diseases.
[24] J. Mellors,et al. The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview , 1996, Transfusion.
[25] D. Stram,et al. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. , 1996, The Journal of infectious diseases.
[26] S. Kleinman,et al. The Risk of Transfusion-Transmitted Viral Infections , 1996 .
[27] J. Hughes,et al. Addressing emerging microbial threats in the United States. , 1996, JAMA.
[28] G. Satten,et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. , 1995, The New England journal of medicine.
[29] C. Nass,et al. The Retrovirus Epidemiology Donor Study (REDS): rationale and methods , 1995, Transfusion.
[30] P. Brown. Can Creutzfeldt-Jakob disease be transmitted by transfusion? , 1995, Current opinion in hematology.
[31] L. Leveton,et al. HIV and the blood supply: an analysis of crisis decision making. , 1995, Transfusion.
[32] D. Stram,et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. , 1995, The Journal of infectious diseases.
[33] H. Alter. To C or not to C: these are the questions. , 1995, Blood.
[34] E. Schiff,et al. Transfusion transmission of retroviruses: human T‐lymphotropic virus types I and II compared with human immunodeficiency virus type 1 , 1994, Transfusion.
[35] J J Goedert,et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. , 1994, Journal of acquired immune deficiency syndromes.
[36] A. Muñoz,et al. The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.
[37] A. Prince,et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. , 1992, Blood.
[38] J. Ward,et al. Human immunodeficiency virus type 1 ‐infected blood donors:behavioral characteristics and reasons for donation , 1991, Transfusion.
[39] J. Ward,et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening , 1991, Transfusion.
[40] S. Azen,et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. , 1990 .
[41] L. Petersen,et al. Methodologic approaches to surveillance of HIV infection among blood donors. , 1990, Public health reports.
[42] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[43] R. Kahn,et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. , 1984, Annals of internal medicine.
[44] H. Alter,et al. Landmark article Feb 15, 1965: A "new" antigen in leukemia sera. By Baruch S. Blumberg, Harvey J. Alter, and Sam Visnich. , 1984, JAMA.
[45] R. Purcell,et al. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. , 1981, JAMA.
[46] R. Kahn,et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. , 1981, The New England journal of medicine.
[47] R. Purcell,et al. NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1977, The Lancet.
[48] R. Purcell,et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. , 1972, Annals of internal medicine.
[49] H. Alter,et al. A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.
[50] P. Beeson. JAUNDICE OCCURRING ONE TO FOUR MONTHS AFTER TRANSFUSION OF BLOOD OR PLASMA: REPORT OF SEVEN CASES , 1943 .
[51] H. Moore,et al. Red blood cell transfusions contaminated with Yersinia enterocolitica--United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. , 1997, MMWR. Morbidity and mortality weekly report.
[52] M. Manco‐Johnson,et al. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995. , 1996, MMWR. Morbidity and mortality weekly report.
[53] Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. , 1983, Connecticut medicine.
[54] H. Goldman,et al. Possible transfusion-associated acquired immune deficiency syndrome (AIDS) - California. , 1982, MMWR. Morbidity and mortality weekly report.